Swedish Biotech Update - Newpharmaresearch Sweden

Newpharmaresearch Sweden AB is a young, fresh company, with a vision to be their clients' centre of excellence, focusing on drug discovery for both human and animal health. The focus on customer service provides a solid and yet adaptable foundation for true partnerships. On every occasion delivering timely and high quality results.

Newpharmaresearch Sweden AB
Founded: 1999
Publicly listed: No
Number of employees: 8
Key business area(s):
Drug discovery
Telephone: +46 46 286 21 10
Website
Contact

A New Beginning, a New Approach

With leading chemist Dr Shoaa Abdul Rahman at the helm of this ambitious company, which operates in cooperation with Lund University and Cairo University, the progress can already be seen. While only in their second year of business, 10 patents have been filed, with four of these patents out-licensed to major pharmaceutical companies.

Novel pharmaceutical molecules
The ‘Gateway to Drug Discovery’ logo describes what Newpharmaresearch Sweden is achieving. The area of expertise is the discovery, development and commercialisation of novel pharmaceutical molecules. Newpharmare-search has designed and synthesized novel pharmaceutical compounds, discovered new uses for and enhanced the activity of existing compounds.
   To prove their capabilities to the world, a disease was identified and solutions were sought to control the disease. Coccidiosis is the single most important disease in the global poultry market, a market worth an estimated $4.1 billion in the year 2000 (Vivash-Jones Consultants Ltd). Additionally, Coccidiosis is shown to have multiple resistance, so new products will be required each year.

Key solutions
The Newpharmaresearch team has come up with key solutions to Coccidiosis, using their three different approaches:
- Organic Synthesis, which resulted in a new Antibiotic Quinolone (Patent No: WO 01/36408 A1) and Novel Urea Compounds (Patent No: WO 01/30749) both, successfully proven to be active against Coccidiosis.
- The second approach is Potentiation, which resulted in a Potentiated Clopidol (Patent No: EPA 0102175-7) this solution has reduced the dosage of the anti-coccidial Clopidol, from 125 grams per tonne to 30 grams per tonnes. The new Potentiated Clopidol has the added advantage of anti-fungal properties in animal feeds.
   Which leads us to New Uses: In a world first, anti-ulcer treatments have been discovered to also work against Coccidiosis. Resulting in Novel Composition (Patent No: EPA 00850205.6).
   Newpharmaresearch has proven they can reach their targets in a time efficient and cost effective way. In this manner, today’s projects are being carried out on, Helicobacter pylori, which is responsible for stomach ulcers and stomach cancer. The Newpharmaresearch team is approaching this insidious bacteria, using the same core competencies, they used against Coccidiosis- Organic Synthesis, Potentiation and discovering New Uses for drugs and/or chemicals.